Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis Research

Executive Summary: Z-VDVAD-FMK (CAS: 210344-92-6) is a peptide-based, irreversible caspase-2 inhibitor used for dissecting apoptotic pathways in cellular models (APExBIO). It covalently binds caspase active site cysteine, inhibiting proteolytic activity and downstream cytochrome c release. The compound is highly soluble (≥34.8 mg/mL) in DMSO, but insoluble in water or ethanol, requiring specific handling for optimal use. Z-VDVAD-FMK has been validated in etoposide- and oxyhemoglobin-induced apoptosis assays, with evidence for both caspase-dependent and independent cell death mechanisms (Li et al., 2025). The reagent is a foundational tool for mitochondrial apoptosis and caspase signaling research, particularly in cancer and neurodegenerative disease models.

Biological Rationale

Caspases are cysteine proteases central to the execution of apoptosis. Caspase-2 is an initiator caspase implicated in DNA damage-induced and mitochondrial apoptosis. Dysregulated caspase pathways underlie cancer, neurodegenerative, and cardiovascular diseases (Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Apoptosis). Selective inhibition of caspase-2 enables mechanistic dissection of cell death pathways and identification of caspase-dependent versus independent events. Z-VDVAD-FMK (benzyloxycarbonyl-Val-Asp(OMe)-Val-Ala-Asp(OMe)-FMK) provides a targeted approach to block caspase-2, with additional activity against caspases-3 and -7, supporting research into mitochondrial cytochrome c release and PARP cleavage events (Z-VDVAD-FMK: Irreversible Caspase-2 Inhibitor for Precision Apoptosis).

Mechanism of Action of Z-VDVAD-FMK

Z-VDVAD-FMK irreversibly inhibits caspase-2 by covalently modifying the active site cysteine residue via its fluoromethyl ketone (FMK) moiety. This modification blocks substrate access and proteolytic activity. The peptide sequence confers enhanced selectivity for caspase-2, but also inhibits caspases-3 and -7 at higher concentrations. In cellular models, Z-VDVAD-FMK prevents the cleavage of key apoptotic substrates, including PARP, and blocks cytochrome c release from mitochondria. These effects result in attenuation of nuclear apoptosis, DNA fragmentation, and cell detachment. However, inhibition is not absolute; certain forms of cell death persist, suggesting alternative, caspase-independent mechanisms may play a role, especially in doxorubicin-treated cells (Li et al., 2025).

Evidence & Benchmarks

• Z-VDVAD-FMK inhibits recombinant human caspase-2 activity in vitro via covalent binding to the active site cysteine (Li et al., DOI).
• In Jurkat T-lymphocyte cells, Z-VDVAD-FMK prevents etoposide-induced cytochrome c release and downstream apoptotic signaling (Li et al., DOI).
• In bovine brain microvessel endothelial cells, Z-VDVAD-FMK reduces oxyhemoglobin-induced apoptosis by decreasing caspase-2 and -3 activity, cell detachment, DNA fragmentation, and PARP cleavage (Li et al., DOI).
• Z-VDVAD-FMK is soluble at ≥34.8 mg/mL in DMSO at 37°C, but insoluble in water and ethanol (APExBIO, product page).
• Long-term storage of Z-VDVAD-FMK solutions is not recommended due to potential loss of activity; solid form is stable below -20°C for months (APExBIO, product page).
• In SVA-infected BHK-21 cells, DDX23 protein is degraded via the caspase-2/-3 pathway, a process that can be dissected using Z-VDVAD-FMK (Li et al., DOI).

Applications, Limits & Misconceptions

Z-VDVAD-FMK is a standard reagent for apoptosis assays, caspase activity measurement, and studies of mitochondrial cytochrome c release inhibition. Its use extends to research on cancer, neurodegenerative disease, and cardiovascular disease apoptosis. The compound enables differentiation of caspase-dependent versus independent cell death and supports mechanistic investigations of signaling pathways relevant to both viral infection and host defense (see Z-VDVAD-FMK: Advanced Caspase-2 Inhibition and Pyroptosis for emerging disease model applications, which this article updates by providing new primary literature benchmarks and solubility data). However, certain misconceptions persist regarding its selectivity, reversibility, and scope of action.

Common Pitfalls or Misconceptions

• Z-VDVAD-FMK is not selective only for caspase-2: At higher concentrations, it can inhibit caspase-3 and -7, potentially confounding pathway analysis (APExBIO).
• Irreversible inhibitor: The covalent mechanism precludes reversal by dilution or washing; incomplete inhibition may reflect caspase-independent mechanisms, not reagent failure.
• Not water or ethanol soluble: Preparation in DMSO is required for full dissolution and functional use.
• Not suitable for long-term solution storage: Activity may decline; prepare fresh solutions before each use.
• Does not prevent all forms of cell death: Some cell death pathways, such as necrosis or certain forms of autophagy, are not blocked by Z-VDVAD-FMK.

Workflow Integration & Parameters

Z-VDVAD-FMK (A1922) is supplied as a solid and should be dissolved in DMSO at concentrations ≥34.8 mg/mL. For optimal solubilization, warm at 37°C for 10 minutes or sonicate briefly. Stock solutions must be stored below -20°C and used within a few months. For apoptosis assays, pre-incubate cells with Z-VDVAD-FMK before the apoptotic stimulus and measure caspase activity, cytochrome c release, PARP cleavage, and downstream apoptosis endpoints. Shipping is performed with blue ice for stability. This reagent is widely referenced for dissecting mitochondrial-dependent apoptotic mechanisms, notably in Jurkat T-lymphocytes and endothelial cells. For a strategic overview on integrating caspase inhibitors in translational workflows, see Strategic Modulation of Mitochondria-Mediated Apoptosis; this article provides updated handling parameters and primary DOI-backed benchmarks.

Conclusion & Outlook

Z-VDVAD-FMK, provided by APExBIO, remains a gold-standard irreversible caspase-2 inhibitor for apoptosis research. Its robust inhibition of mitochondrial cytochrome c release and PARP cleavage enables precise dissection of the caspase signaling cascade. While it is not selective solely for caspase-2 and does not prevent all forms of cell death, its characterized solubility and workflow parameters make it indispensable in cancer, neurodegenerative, and cardiovascular research. Ongoing studies continue to refine its use in disease modeling and in mapping caspase-dependent antiviral responses (Li et al., 2025).